[{"id":"d6bf4390-80d2-48a6-a20b-b3b33e8ad438","acronym":"","url":"https://clinicaltrials.gov/study/NCT00522145","created_at":"2021-01-18T01:53:09.959Z","updated_at":"2024-07-02T16:36:10.496Z","phase":"Phase 2","brief_title":"Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib","source_id_and_acronym":"NCT00522145","lead_sponsor":"Kadmon Corporation, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • gefitinib • tesevatinib (KD019)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 05/01/2007","start_date":" 05/01/2007","primary_txt":" Primary completion: 10/01/2009","primary_completion_date":" 10/01/2009","study_txt":" Completion: 02/01/2010","study_completion_date":" 02/01/2010","last_update_posted":"2022-05-13"},{"id":"aa2c301e-78e0-4981-a17e-6a53b1eb1bc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02616393","created_at":"2021-01-18T12:42:35.477Z","updated_at":"2024-07-02T16:36:15.309Z","phase":"Phase 2","brief_title":"Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases","source_id_and_acronym":"NCT02616393","lead_sponsor":"Kadmon Corporation, LLC","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tesevatinib (KD019)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 04/03/2018","primary_completion_date":" 04/03/2018","study_txt":" Completion: 04/03/2018","study_completion_date":" 04/03/2018","last_update_posted":"2022-03-16"}]